Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02205840 · ClinicalTrials.gov registry record · Phase 2
A Clinical Study Evaluating the Safety and Efficacy of SI-614 Ophthalmic Solution in Patients With Dry Eye.
A Phase 2 study of Dry Eye Syndromes, sponsored by Seikagaku Corporation.
- Completed
- Registry status
- Phase 2
- Development phase
- 240
- Enrollment target
- 1
- Study location
NCT02205840: Completed Phase 2 study of Dry Eye Syndromes, sponsored by Seikagaku Corporation.
NCT02205840 is a Phase 2 study of Dry Eye Syndromes that has completed, run by Seikagaku Corporation. The registered enrollment target is 240 participants, below the 400-participant average among 17 other Dry Eye Syndromes trials with a reported enrollment target (40% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02205840, a Phase 2 study of Dry Eye Syndromes, has completed, sponsored by Seikagaku Corporation.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 240 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to assess the safety and effectiveness of SI-614 solution compared with placebo solution in treating patients with dry eye.
Conditions Studied
Interventions
- DRUG Vehicle
- DRUG SI-614
Study Locations (1)
Massachusetts
- - Andover
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 240 participants |
| Start Date | 2014-07 |
| Phase | Phase 2 |
What the finished NCT02205840 record still lists
NCT02205840 is an interventional study that assigns participants to a tested intervention. The registered 240 participants enrollment target is mid-sized for trials with a published cap, below the 400-participant average among 17 other Dry Eye Syndromes trials with a reported enrollment target (40% lower).
The record links to 1 condition, with Dry Eye Syndromes appearing as the primary indexed condition, and to 2 interventions - of which Vehicle is the first listed.
NCT02205840 reports a single indexed study location in Massachusetts.
Frequently Asked Questions
What is clinical trial NCT02205840 about?
NCT02205840 is a clinical study titled "A Clinical Study Evaluating the Safety and Efficacy of SI-614 Ophthalmic Solution in Patients With Dry Eye.". The purpose of this study is to assess the safety and effectiveness of SI-614 solution compared with placebo solution in treating patients with dry eye.
What is the current status of trial NCT02205840?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 240 participants. The study started on 2014-07.
What conditions does trial NCT02205840 study?
This clinical trial studies the following conditions: Dry Eye Syndromes.
What interventions are being tested in trial NCT02205840?
The interventions under investigation include: Vehicle (DRUG), SI-614 (DRUG).
Who is sponsoring clinical trial NCT02205840?
This trial is sponsored by Seikagaku Corporation, which has 12 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02205840 being conducted?
This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Dry Eye Syndromes
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02205840's enrollment target sits among peer trials
240 3rd of 17 higher than 15 of 17 other Dry Eye Syndromes trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Dry Eye Syndromes trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Clinical Study Evaluating the Safety and Efficacy of SI-614 Ophthalmic Solution in Patients With Dry Eye
COMPLETED · Phase 2
-
Safety and Efficacy Study of Rebamipide 2% Ophthalmic Suspension in Patients With Dry Eye
COMPLETED · Phase 2
-
CyclASol for the Treatment of Moderate to Severe Dry-eye Disease (DED)
COMPLETED · Phase 2
-
Dry Eye Assessment and Management: Feasibility Study
COMPLETED · Phase 2
-
Clinical Applications of Advanced Ophthalmic Imaging
RECRUITING · NA
-
Efficacy of OmegaBoost to Increase Omega-3 Levels in Healthy Individuals
ACTIVE NOT RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02855554 · 240 participants · NA
Quantitative Cardiac Parametric Mapping
- NCT03230565 · 240 participants · Phase 4
Continuous Infusions vs Scheduled Bolus Infusions
- NCT03399929 · 240 participants
Traumatic Brain Injury and Stroke Long Term Outcome
- NCT03583710 · 240 participants · Phase 3
Mitotane With or Without Cisplatin and Etoposide After Surgery in Treating Patients With Stage I-III Adrenocortical Cancer With High Risk of Recurrence
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia